108 related articles for article (PubMed ID: 10547193)
21. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand.
O'Connell J; O'Sullivan GC; Collins JK; Shanahan F
J Exp Med; 1996 Sep; 184(3):1075-82. PubMed ID: 9064324
[TBL] [Abstract][Full Text] [Related]
22. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression.
Mishima K; Nariai Y; Yoshimura Y
Int J Cancer; 2003 Jul; 105(5):593-600. PubMed ID: 12740905
[TBL] [Abstract][Full Text] [Related]
23. Alpha-fetoprotein triggers hepatoma cells escaping from immune surveillance through altering the expression of Fas/FasL and tumor necrosis factor related apoptosis-inducing ligand and its receptor of lymphocytes and liver cancer cells.
Li MS; Ma QL; Chen Q; Liu XH; Li PF; Du GG; Li G
World J Gastroenterol; 2005 May; 11(17):2564-9. PubMed ID: 15849812
[TBL] [Abstract][Full Text] [Related]
24. Over-expressed Fas improves the apoptosis of malignant T-cells in vitro and vivo.
Li L; Zhang R; Chen Z; Xue S; Wang X; Ruan C
Mol Biol Rep; 2011 Nov; 38(8):5371-7. PubMed ID: 21390503
[TBL] [Abstract][Full Text] [Related]
25. Overexpression of Fas ligand does not confer immune privilege to a pancreatic beta tumor cell line (betaTC-3).
Okamoto S; Takamizawa S; Bishop W; Wen J; Kimura K; Sandler A
J Surg Res; 1999 Jun; 84(1):77-81. PubMed ID: 10334893
[TBL] [Abstract][Full Text] [Related]
26. Serial in vivo loss and in vitro gain of Fas expression and function in human cancerous pancreatic duct cells.
Radfar S; Davrinche C; Hollande E
Int J Cancer; 2005 Jun; 115(2):214-23. PubMed ID: 15688389
[TBL] [Abstract][Full Text] [Related]
27. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors.
Satoh K; Kaneko K; Hirota M; Masamune A; Satoh A; Shimosegawa T
Cancer; 2001 Jul; 92(2):271-8. PubMed ID: 11466679
[TBL] [Abstract][Full Text] [Related]
28. CD95 ligand expression as a mechanism of immune escape in breast cancer.
Müschen M; Moers C; Warskulat U; Even J; Niederacher D; Beckmann MW
Immunology; 2000 Jan; 99(1):69-77. PubMed ID: 10651943
[TBL] [Abstract][Full Text] [Related]
29. Intracellular Fas ligand in normal and malignant breast epithelium does not induce apoptosis in Fas-sensitive cells.
Ragnarsson GB; Mikaelsdottir EK; Vidarsson H; Jónasson JG; Olafsdóttir K; Kristjánsdóttir K; Kjartansson J; Ogmundsdóttir HM; Rafnar T
Br J Cancer; 2000 Dec; 83(12):1715-21. PubMed ID: 11104571
[TBL] [Abstract][Full Text] [Related]
30. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma.
Viard-Leveugle I; Veyrenc S; French LE; Brambilla C; Brambilla E
J Pathol; 2003 Oct; 201(2):268-77. PubMed ID: 14517844
[TBL] [Abstract][Full Text] [Related]
31. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma.
Bellone G; Smirne C; Carbone A; Mareschi K; Dughera L; Farina EC; Alabiso O; Valente G; Emanuelli G; Rodeck U
Clin Cancer Res; 2000 Jun; 6(6):2448-55. PubMed ID: 10873098
[TBL] [Abstract][Full Text] [Related]
32. Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion.
Mitsiades N; Poulaki V; Mastorakos G; Tseleni-Balafouta ST; Kotoula V; Koutras DA; Tsokos M
J Clin Endocrinol Metab; 1999 Aug; 84(8):2924-32. PubMed ID: 10443700
[TBL] [Abstract][Full Text] [Related]
33. [CD95 resistance and Fas ligand synthesis as mechanism of defense by immunocompetent cells in pancreatic tumors].
Ungefroren H; Voss M; Henne-Bruns D; Kremer B; Kalthoff H
Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):63-7. PubMed ID: 14518214
[TBL] [Abstract][Full Text] [Related]
34. Expression of apoptotic regulatory molecules in renal cell carcinoma: elevated expression of Fas ligand.
Olive C; Cheung C; Nicol D; Falk MC
Immunol Cell Biol; 1999 Feb; 77(1):11-8. PubMed ID: 10101681
[TBL] [Abstract][Full Text] [Related]
35. Resistance to Fas-mediated cell death in BeWo and NJG choriocarcinoma cell lines: implications in immune privilege.
Rajashekhar G; Loganath A; Roy AC; Mongelli JM
Gynecol Oncol; 2003 Oct; 91(1):89-100. PubMed ID: 14529667
[TBL] [Abstract][Full Text] [Related]
36. Fas ligand (FasL, CD95L, APO-1L) expression in murine mast cells.
Wagelie-Steffen AL; Hartmann K; Vliagoftis H; Metcalfe DD
Immunology; 1998 Aug; 94(4):569-74. PubMed ID: 9767446
[TBL] [Abstract][Full Text] [Related]
37. Double-negative T Cells Inhibit Proliferation and Invasion of Human Pancreatic Cancer Cells in Co-culture.
Lu Y; Hu P; Zhou H; Yang Z; Sun YU; Hoffman RM; Chen J
Anticancer Res; 2019 Nov; 39(11):5911-5918. PubMed ID: 31704815
[TBL] [Abstract][Full Text] [Related]
38. Fas ligand expression in human pancreatic cancer.
Ohta T; Elnemr A; Kitagawa H; Kayahara M; Takamura H; Fujimura T; Nishimura G; Shimizu K; Yi SQ; Miwa K
Oncol Rep; 2004 Oct; 12(4):749-54. PubMed ID: 15375495
[TBL] [Abstract][Full Text] [Related]
39. Apoptosis induced in T cells by human neuroblastoma cells: role of Fas ligand.
Shurin GV; Gerein V; Lotze MT; Barksdale EM
Nat Immun; 1998; 16(5-6):263-74. PubMed ID: 11061594
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic carcinoma cells express neuropilins and vascular endothelial growth factor, but not vascular endothelial growth factor receptors.
Li M; Yang H; Chai H; Fisher WE; Wang X; Brunicardi FC; Yao Q; Chen C
Cancer; 2004 Nov; 101(10):2341-50. PubMed ID: 15476280
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
